ATE478142T1 - Behandlung von melanomen durch reduktion der clusterin menge - Google Patents

Behandlung von melanomen durch reduktion der clusterin menge

Info

Publication number
ATE478142T1
ATE478142T1 AT03792074T AT03792074T ATE478142T1 AT E478142 T1 ATE478142 T1 AT E478142T1 AT 03792074 T AT03792074 T AT 03792074T AT 03792074 T AT03792074 T AT 03792074T AT E478142 T1 ATE478142 T1 AT E478142T1
Authority
AT
Austria
Prior art keywords
clusterin
subject
amount
bcl
treatment
Prior art date
Application number
AT03792074T
Other languages
English (en)
Inventor
Burkhard Jansen
Martin Gleave
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE478142T1 publication Critical patent/ATE478142T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03792074T 2002-08-21 2003-08-21 Behandlung von melanomen durch reduktion der clusterin menge ATE478142T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (1)

Publication Number Publication Date
ATE478142T1 true ATE478142T1 (de) 2010-09-15

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792074T ATE478142T1 (de) 2002-08-21 2003-08-21 Behandlung von melanomen durch reduktion der clusterin menge

Country Status (16)

Country Link
US (1) US7285541B2 (de)
EP (1) EP1530636B1 (de)
JP (1) JP4620585B2 (de)
KR (1) KR101052289B1 (de)
AT (1) ATE478142T1 (de)
AU (1) AU2003258425B2 (de)
CA (1) CA2494764C (de)
CY (1) CY1110936T1 (de)
DE (1) DE60333839D1 (de)
DK (1) DK1530636T3 (de)
IL (1) IL166657A (de)
NO (1) NO333254B1 (de)
NZ (1) NZ538288A (de)
PT (1) PT1530636E (de)
SI (1) SI1530636T1 (de)
WO (1) WO2004018675A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ533126A (en) 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
ATE478142T1 (de) 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CN101389345A (zh) * 2004-03-19 2009-03-18 宾州研究基金会 治疗黑素瘤的组合方法和组合物
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
AU2006292293B2 (en) * 2005-09-19 2012-09-13 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
EP2190870A4 (de) * 2007-08-28 2010-12-01 Auckland Uniservices Ltd Zellmarker einer melanozytenzelllinie und verwendung davon
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
BR112013023452A2 (pt) 2011-03-15 2016-12-06 Univ British Columbia combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
EA201491568A1 (ru) 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
WO2014159775A1 (en) * 2013-03-14 2014-10-02 Teva Pharmaceutical Industries Ltd. Anti-clusterin monotherapy for cancer treatment
JP2025505396A (ja) * 2022-01-26 2025-02-26 アイデックス ラボラトリーズ インコーポレイテッド 進行性慢性腎疾患を安定慢性腎疾患と区別するための方法及び組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100768109B1 (ko) * 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
ATE478142T1 (de) 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Also Published As

Publication number Publication date
JP2006502243A (ja) 2006-01-19
JP4620585B2 (ja) 2011-01-26
IL166657A (en) 2010-05-31
KR101052289B1 (ko) 2011-07-27
KR20050058425A (ko) 2005-06-16
PT1530636E (pt) 2010-11-17
NO20051426L (no) 2005-05-12
NO333254B1 (no) 2013-04-22
AU2003258425B2 (en) 2008-02-14
EP1530636B1 (de) 2010-08-18
EP1530636A1 (de) 2005-05-18
NZ538288A (en) 2008-04-30
CY1110936T1 (el) 2015-06-10
US20040082534A1 (en) 2004-04-29
CA2494764A1 (en) 2004-03-04
SI1530636T1 (sl) 2010-12-31
US7285541B2 (en) 2007-10-23
AU2003258425A1 (en) 2004-03-11
CA2494764C (en) 2013-04-23
DK1530636T3 (da) 2010-11-29
IL166657A0 (en) 2006-01-15
WO2004018675A1 (en) 2004-03-04
DE60333839D1 (de) 2010-09-30

Similar Documents

Publication Publication Date Title
CY1110936T1 (el) Θεραπεια μελανωματος με μειωση των επιπεδων της clusterin
Lee et al. Brazilin inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing the NF-κB pathway in human dermal fibroblasts
WO2000049937A3 (en) Trpm-2 antisense therapy
WO2007085018A3 (en) Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
MX9703694A (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
SE0301888D0 (sv) New use VII
SE0301882D0 (sv) New use I
ATE353010T1 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
NO20033665L (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
EP4640281A3 (de) Hemmung von metastasen durch verbindungen die den persistenten teil des spannungsgesteuerten natriumkanals hemmen
Ganguly et al. Skin aging: implications of UV radiation, reactive oxygen species and natural antioxidants
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
Sheipouri et al. RETRACTED: Characterisation of the Kynurenine Pathway in Skin‐Derived Fibroblasts and Keratinocytes
MX339096B (es) Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
TR200100611T2 (tr) İbuprofen ve domperidon içeren farmasötik kompozisyonlar
TW200515914A (en) Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
AU3934000A (en) Inhibitors of endothelin-1 synthesis
Park et al. Effects of xanthium stramarium and psoralea corylifolia extracts combined with UVA1 irradiation on the cell proliferation and TGF-β1 expression of keloid fibroblasts
SE0301883D0 (sv) New use II
ATE294811T1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
SE0301885D0 (sv) New use IV

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1530636

Country of ref document: EP